期刊
CANCER CELL
卷 24, 期 6, 页码 751-765出版社
CELL PRESS
DOI: 10.1016/j.ccr.2013.10.013
关键词
-
资金
- National Institutes of Health
- SPORE [P50 CA105009]
- EDRN [U01 CA152990, R21 CA156021]
- DOD OCRP [W81XWH-10-1-0263]
- American Cancer Society [RSG-13-083-01-TBG]
- Ovarian Cycle and Ovarian Cancer Research Fund Liz Tilberis award
- Burroughs-Wellcome Fund Career Award in the Biomedical Sciences [1005320.01]
- V Foundation for Cancer Research Scholar Award
- Marsha Rivkin Foundation for Ovarian Cancer Research
- Mildred Moorman Ovarian Cancer Research Fund
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Ovarian Cancer Research Fund Ann Schreiber award
- National Ovarian Cancer Coalition
- Mary Kay Foundation
- Sandy Rollman Ovarian Cancer Foundation
- Susan Smith Center for Women's Cancers at the Dana-Farber Cancer Institute
- Debra and Robert First Fund
- Gamel Family Fund
- Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine Award
High-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges. Although the traditional model of carcinogenesis has focused on the ovary as a tumor initiation site, recent studies suggest that there may be additional sites of origin outside the ovary, namely the secretory cells of the fallopian tube. Our study demonstrates that high-grade serous tumors can originate in fallopian tubal secretory epithelial cells and also establishes serous tubal intraepithelial carcinoma as the precursor lesion to high-grade serous ovarian and peritoneal carcinomas in animal models targeting the Brca, Tp53, and Pten genes. These findings offer an avenue to address clinically important questions that are critical for cancer prevention and early detection in women carrying BRCA1 and BRCA2 mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据